Bharat Immunologicals (India) Financial Diagnostics

Bharat Immunologicals diagnostics interface makes it easy to digest most current publicly released information about Bharat Immunologicals as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis Bharat Immunologicals price relationship with some important fundamental indicators such as market cap and management efficiency.

Bharat Immunologicals Alerts

Bharat Immunologicals appears to be very risky and stock price may revert if volatility continues
The company reported revenue of 1.28 B. Net Loss for the year was (53.46 M) with profit before overhead, payroll, taxes, and interest of 119 M.

Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 1.5 B.


The company has Profit Margin (PM) of (4.18) % which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (5.13) % which suggests for every $100 dollars of sales it generated a net operating loss of -0.05.


The company recorded loss per share of 1.24. Bharat Immunologicals Biologicals Corp Ltd had not issued any dividends in recent years. Bharat Immunologicals & Biologicals Corporation Limited, a biotechnology company, manufactures and markets a range of pharmaceuticals solutions in India. For more info on BHARAT IMUNO(BSE please contact the company at 91 57 3223 8758 or go to

Management Efficiency

Bharat Immunologicals Biologicals Corp Ltd has return on total asset (ROA) of (1.69) % which means that it has lost $1.69 on every $100 spent on asset. This is way below average.